GLP-1
Albiglutide
SaveA once-weekly GLP-1 receptor agonist (brand name Tanzeum) that was FDA-approved for type 2 diabetes but voluntarily withdrawn from the market in 2018 for commercial reasons.
Quick verdict
Proven glycemic efficacy but less weight loss than newer GLP-1 RAs. No longer commercially available.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
The HARMONY outcomes trial demonstrated cardiovascular benefit. Glycemic efficacy was established in the HARMONY Phase III program. Weight loss was modest compared to liraglutide and semaglutide. Withdrawal was due to low market uptake, not safety.
Benefits
- Demonstrated cardiovascular risk reduction (HARMONY)
- Once-weekly dosing convenience
- Established glycemic efficacy in Phase III
Dosage notes
Was dosed at 30–50 mg subcutaneously once weekly.
Side effects
- Nausea
- Injection site reactions
- Diarrhea
Who should be cautious
No longer manufactured. Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. GI side effects are common with all GLP-1 RAs.
What this page cannot tell you
Market withdrawal limits practical relevance. Cardiovascular outcome data was positive but the trial completed after commercial withdrawal.
Leaderboard scores
- Weight loss45
Write a review
Sign in to write a review.